AQR Capital Management LLC lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 1.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,489,218 shares of the biotechnology company’s stock after selling 25,345 shares during the quarter. AQR Capital Management LLC owned 5.68% of United Therapeutics worth $292,160,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in UTHR. Oregon Public Employees Retirement Fund lifted its holdings in United Therapeutics by 10,537.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 3,517,845 shares during the period. Norges Bank acquired a new stake in United Therapeutics in the fourth quarter valued at $54,233,000. First Trust Advisors LP raised its stake in shares of United Therapeutics by 13.6% during the 4th quarter. First Trust Advisors LP now owns 1,196,804 shares of the biotechnology company’s stock worth $130,332,000 after buying an additional 143,235 shares during the last quarter. Pictet Asset Management Ltd. raised its stake in shares of United Therapeutics by 64.0% during the 1st quarter. Pictet Asset Management Ltd. now owns 266,163 shares of the biotechnology company’s stock worth $31,240,000 after buying an additional 103,840 shares during the last quarter. Finally, Macquarie Group Ltd. raised its stake in shares of United Therapeutics by 855.9% during the 4th quarter. Macquarie Group Ltd. now owns 112,800 shares of the biotechnology company’s stock worth $12,284,000 after buying an additional 101,000 shares during the last quarter. 96.47% of the stock is owned by institutional investors.
Several research analysts have recently issued reports on UTHR shares. Wedbush set a $269.00 price target on United Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 8th. BidaskClub raised United Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Oppenheimer set a $160.00 price target on United Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 26th. LADENBURG THALM/SH SH set a $124.00 price target on United Therapeutics and gave the stock a “hold” rating in a research note on Thursday, February 28th. Finally, Cowen reaffirmed a “hold” rating and set a $109.00 price target on shares of United Therapeutics in a research note on Wednesday, February 27th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. United Therapeutics presently has a consensus rating of “Hold” and an average target price of $129.00.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($13.96). The company had revenue of $362.70 million for the quarter, compared to analysts’ expectations of $335.72 million. United Therapeutics had a negative return on equity of 5.78% and a negative net margin of 9.36%. The company’s revenue for the quarter was down 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.76 EPS. On average, analysts expect that United Therapeutics Co. will post -5.03 EPS for the current fiscal year.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
See Also: Exchange-Traded Funds (ETFs)
